TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21437746

Group type: EXPERIMENTAL
Intervention: Transanal tube
Number of subjects: 398

Group type: COMPARATOR
Intervention: No transanal tube
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Transanal tube (double-staple technique subgroup)
Number of subjects: 398

Group type: COMPARATOR
Intervention: No transanal tube (double-staple technique subgroup)
Number of subjects: 398
Study: 18201641

Group type: EXPERIMENTAL
Intervention: Behavioral Internet Treatment (BIT)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 446
Study: 16387937

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure support of 10 cmH2O
Number of subjects: 29

Group type: COMPARATOR
Intervention: Inspiratory pressure support of 5 cmH2O (Control)
Number of subjects: 29
Study: 12590028

Group type: EXPERIMENTAL
Intervention: Survey at 2 weeks after death
Number of subjects: 207

Group type: COMPARATOR
Intervention: Survey at 6 weeks after death
Number of subjects: 207
Study: 11199864

Group type: EXPERIMENTAL
Intervention: 10 mg ISDN
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 20 mg ISDN
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 20 mg SR ISDN
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 40 mg SR ISDN
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 40 mg SR ISDN (3x dosing)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 38
Study: 8776643

Group type: EXPERIMENTAL
Intervention: ANP 7.5 pMol/kg/min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle alone (C)
Number of subjects: 30
Study: 1362228

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 2
Study: 6749207

Group type: EXPERIMENTAL
Intervention: Fibrinogen level
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Serum cholesterol
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 792
Study: 30854986

Group type: EXPERIMENTAL
Intervention: 2.7 g/d of DHA
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 2.7 g/d of EPA
Number of subjects: 154

Group type: COMPARATOR
Intervention: 3 g/d of maize oil
Number of subjects: 154
Study: 29481661

Group type: EXPERIMENTAL
Intervention: golimumab
Number of subjects: 216

Group type: COMPARATOR
Intervention: infliximab (IMPACT 2)
Number of subjects: 216
Study: 27593504

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (100 μg) and vilanterol (25 μg) once daily
Number of subjects: 2799

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2799
Study: 24573180

Group type: COMPARATOR
Intervention: Hyperoxic PECO (FiO2 = 1.0)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hypoxic PECO (target SPo2 = 85%)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Normoxic PECO (room air)
Number of subjects: 14
Study: 22231020

Group type: EXPERIMENTAL
Intervention: High concentrate (450 g/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moderate concentrate (300 g/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low concentrate (150 g/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Crossbred goats
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Local goats
Number of subjects: 36
Study: 20102936

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for 48 hours before and 48 hours after contrast medium administration
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 18854539

Group type: EXPERIMENTAL
Intervention: High-dose B vitamin supplementation (5 mg/d of folate, 25 mg/d of vitamin B(6), 1 mg/d of vitamin B(12))
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: High-dose B vitamin supplementation
Number of subjects: 409
Study: 15892275

Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI) plus conventional western medicine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional western medicine (Control)
Number of subjects: 56
Study: 12038847

Group type: EXPERIMENTAL
Intervention: Beta-tricalcium phosphate (beta-TCP) bone void filler as an additive to autogenous bone graft material
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autogenous bone graft material
Number of subjects: 0
Study: 10404806

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy, initial dose of 1-3 IU/m2 x day (9-27 microg/kg), tapered to 1.30+/−0.38 IU/m2 x day (11 g/kg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 38
Study: 7570327

Group type: EXPERIMENTAL
Intervention: Antimicrobial regimens with surgical or percutaneous drainage
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (patients without enterococcus)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Overall treatment regimens
Number of subjects: 330
Study: 2202385

Group type: EXPERIMENTAL
Intervention: Active treatment with levodopa/carbidopa (Sinemet Plus)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Active treatment and placebo
Number of subjects: 14
Study: 7196705

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 100 mg IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyzine with naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone alone
Number of subjects: 0
Study: 31860597

Group type: EXPERIMENTAL
Intervention: Simulated patient teaching session (n=73)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard clinician-supervised learning in the operating theatre (n=71)
Number of subjects: 144
Study: 31213078

Group type: EXPERIMENTAL
Intervention: Traditional hospital preoperative total knee arthroplasty education program with an additional 30‐minute group pain neuroscience education session
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional hospital preoperative total knee arthroplasty education program
Number of subjects: 120
Study: 26992420

Group type: EXPERIMENTAL
Intervention: FD-OCT
Number of subjects: 13418

Group type: COMPARATOR
Intervention: IVUS
Number of subjects: 13418
Study: 26193218

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 33

Group type: COMPARATOR
Intervention: Histopathology
Number of subjects: 33
Study: 22456951

Group type: EXPERIMENTAL
Intervention: DEN (200 mg/kg body weight) followed by 2-acetylamino fluorine (150 mg/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 21342217

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/RTV) 300/100 mg every 24 h for 14 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) 400 mg every 24 h for 14 days
Number of subjects: 24
Study: 19522655

Group type: EXPERIMENTAL
Intervention: PCV7 followed 2 months later by PPV23
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV7 followed 6 months later by PPV23
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPV23
Number of subjects: 0
Study: 16865614

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Surgical gastrostomy (SG)
Number of subjects: 70
Study: 12629374

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Electrovaporization
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 141
Study: 11113837

Group type: COMPARATOR
Intervention: Biofeedback therapy (BF) alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BF) + oral laxatives (LAX)
Number of subjects: 48
Study: 9288198

Group type: EXPERIMENTAL
Intervention: Linear vestibulo-ocular reflexes (LVOR) measured during lateral whole-body translation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal cases (control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Patients with mild LVOR asymmetries
Number of subjects: 14
Study: 8421417

Group type: EXPERIMENTAL
Intervention: Cefixime (once-a-day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Amoxicillin (three times a day)
Number of subjects: 114
Study: 3524724

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Gluten-containing diet (control)
Number of subjects: 24
Study: 29480198

Group type: EXPERIMENTAL
Intervention: 1.5-hour multisensory virtual simulation experience
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard curriculum only
Number of subjects: 278
Study: 26871692

Group type: EXPERIMENTAL
Intervention: Electrical stimulation group (18-32 min pulsed current, stimulation frequency 80 Hz, pulse duration 400 μs, stimulation intensity 40% of maximal isometric voluntary contraction)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined group (electrical stimulation plus laser therapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Laser group (dose 4-6 J per point, 6 points at the knee joint)
Number of subjects: 45

Group type: COMPARATOR
Intervention: All groups (including control period)
Number of subjects: 45
Study: 24755192

Group type: EXPERIMENTAL
Intervention: m-TOR therapy (SRL and EVL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: m-TOR therapy
Number of subjects: 30
Study: 23203669

Group type: EXPERIMENTAL
Intervention: Number of physicians per 10,000 persons in Europe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of physicians per 10,000 persons in Asia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Region as a function of the number of physicians
Number of subjects: 0
Study: 21302489

Group type: EXPERIMENTAL
Intervention: Shaogen Decoction (SGD) administered 10 mL, thrice a day, increased to every 2 hours if 2nd or over 2nd grade ARE occurred.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group treated with antibiotics (cefuroxime 4.5 g) and hormone (dexamethasone 5 mg) by intravenous infusion for 7 days.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SGD group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 18394624

Group type: EXPERIMENTAL
Intervention: Polyethylene covers (Gladwrap)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Lanolin eye ointment (Duratears)
Number of subjects: 116
Study: 16340472

Group type: EXPERIMENTAL
Intervention: Clinician-delivered intervention
Number of subjects: 497

Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 497
Study: 15536894

Group type: EXPERIMENTAL
Intervention: Diabetes patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 26
Study: 11550964

Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfasalazine 2 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (switched to sulfasalazine at Month 6)
Number of subjects: 0
Study: 9663720

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg for 10 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Methylprednisolone 32 mg for 3 weeks with tapering
Number of subjects: 29
Study: 7819986

Group type: EXPERIMENTAL
Intervention: Whisky
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Brandy
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Whisky and Brandy
Number of subjects: 4
Study: 3065267

Group type: EXPERIMENTAL
Intervention: Oral minocycline
Number of subjects: 96

Group type: COMPARATOR
Intervention: Topical tetracycline ointment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 96
Study: 30595284

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting coronary stents
Number of subjects: 204

Group type: COMPARATOR
Intervention: Biodegradable polymer-based sirolimus-eluting coronary stents
Number of subjects: 204
Study: 28512843

Group type: EXPERIMENTAL
Intervention: New brightening complex cream containing niacinamide, tranexamic acid, oxyresveratrol, glutathione disulfide, and linoleic acid applied on the face two times per day for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: New brightening complex cream
Number of subjects: 26
Study: 26387055

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (400 mcg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Intra-arterial nitroglycerin (200 mcg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (400 mcg) in patients < 1.65 m height
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (400 mcg) in patients with diabetes
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (400 mcg) in smokers
Number of subjects: 101
Study: 23107873

Group type: EXPERIMENTAL
Intervention: S18886 30 mg/d for 5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21959813

Group type: EXPERIMENTAL
Intervention: Morphine (2 or 4 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pethidine (25 or 50 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fentanyl (50 μg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All opioids (morphine, pethidine, fentanyl)
Number of subjects: 50

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 50
Study: 18294482

Group type: COMPARATOR
Intervention: Dalteparin 120 IU/kg s.c. (maximum 10,000 IU) twice daily for 5 to 7 days in hospital, followed by placebo for 3 months (n = 285)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Sex- and weight-adjusted doses of dalteparin (5000 or 7500 IU) twice daily for 3 months (n = 270)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Dalteparin treatment
Number of subjects: 555

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 555
Study: 16169705

Group type: COMPARATOR
Intervention: Modified Reliable Change Index (RCI) methodology applied across a battery of neuropsychological tests
Number of subjects: 57

Group type: COMPARATOR
Intervention: Battery change scores calculated by summing z-scores of change for each individual test
Number of subjects: 57

Group type: COMPARATOR
Intervention: Battery RCI normative standards
Number of subjects: 57
Study: 14648082

Group type: EXPERIMENTAL
Intervention: Patient education program for ankylosing spondylitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10624992

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (20 mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (20 mL)
Number of subjects: 50
Study: 9179174

Group type: EXPERIMENTAL
Intervention: Low-impact aerobic exercise for 12 weeks
Number of subjects: 25
Study: 23087954

Group type: EXPERIMENTAL
Intervention: Prophylaxis with a rubber cup and pumice
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prophylaxis with a rubber cup and nonfluoridated paste
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prophylaxis with a rubber cup and fluoridated paste
Number of subjects: 45
Study: 3757512

Group type: EXPERIMENTAL
Intervention: Microgynon 30 (150 micrograms levonorgestrel and 30 micrograms ethinyl oestradiol)
Number of subjects: 14
Study: 31736123

Group type: EXPERIMENTAL
Intervention: Single Ablative Fractional Resurfacing Laser Treatment (FLR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated arm)
Number of subjects: 30
Study: 29033355

Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia tramadol + SAPB (Group S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia tramadol (Group T)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 27067393

Group type: EXPERIMENTAL
Intervention: Topical diclofenac 3% gel
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Combination therapy (diclofenac and calcitriol)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no topical treatment)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Topical calcitriol 3 μg/g ointment
Number of subjects: 128
Study: 24316342

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide
Number of subjects: 92
Study: 22652344

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1521) and AIDSVAX B/E vaccine regimen
Number of subjects: 16395

Group type: EXPERIMENTAL
Intervention: High or increasing risk behaviour
Number of subjects: 16395

Group type: COMPARATOR
Intervention: Vaccination
Number of subjects: 16395
Study: 20633581

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18783504

Group type: EXPERIMENTAL
Intervention: bupropion sustained-release (SR) treatment
Number of subjects: 403

Group type: COMPARATOR
Intervention: placebo pill
Number of subjects: 403
Study: 15629356

Group type: EXPERIMENTAL
Intervention: Hexavalent DTPa-HBV-IPV/Hib vaccine
Number of subjects: 9199

Group type: COMPARATOR
Intervention: DTPa-IPV/Hib and HBV vaccines administered separately
Number of subjects: 9199
Study: 14521290

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Open subacromial decompression (OSD)
Number of subjects: 34
Study: 9882287

Group type: EXPERIMENTAL
Intervention: cpts530/1030
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cpts248/404/1030
Number of subjects: 0

Group type: COMPARATOR
Intervention: cpts248/404
Number of subjects: 0
Study: 8742147

Group type: EXPERIMENTAL
Intervention: Infectious conditions
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Respiratory infections
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Total infections
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Infections by month
Number of subjects: 474
Study: 1750315

Group type: EXPERIMENTAL
Intervention: 0.25% clonidine
Number of subjects: 63

Group type: COMPARATOR
Intervention: saline
Number of subjects: 63
Study: 7038491

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 31814044

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (intravenous magnesium sulfate to maintain serum magnesium level around 3 mg/dL for 3 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 31388184

Group type: EXPERIMENTAL
Intervention: Combined protein biomarker panel (CA125, phosphatidylcholine‐sterol acyltransferase, vitamin K‐dependent protein Z and C‐reactive protein)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combined protein biomarker panel
Number of subjects: 49
Study: 29702040

Group type: EXPERIMENTAL
Intervention: Whole grains diet
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination diet (whole grains and fruits and vegetables)
Number of subjects: 75
Study: 27104803

Group type: EXPERIMENTAL
Intervention: Continuation cognitive therapy (C-CT)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Pill placebo (PBO) plus clinical management
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Acute-phase cognitive therapy (CT)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Deteriorating social-interpersonal functioning
Number of subjects: 241
Study: 25058804

Group type: EXPERIMENTAL
Intervention: Bladder distention before outpatient hysteroscopy (OH)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No bladder distention (control group)
Number of subjects: 102
Study: 22134624

Group type: EXPERIMENTAL
Intervention: 1 mg minodronate once a day
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo (first 2 years) then minodronate (year 3)
Number of subjects: 380
Study: 19496635

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 124

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 124
Study: 17205494

Group type: EXPERIMENTAL
Intervention: Multilayer compression treatment with ULSA score of 50 or less
Number of subjects: 229

Group type: COMPARATOR
Intervention: Multilayer compression treatment with ULSA score of greater than 50
Number of subjects: 229
Study: 16008934

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 52
Study: 12090459

Group type: EXPERIMENTAL
Intervention: Zinc acetate (low stability constant)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zinc gluconate (low stability constant)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zinc citrate (high stability constant)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amino-acid chelated zinc (extremely high stability constant)
Number of subjects: 10
Study: 11193270

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (Epidural bupivacaine and Intravenous morphine)
Number of subjects: 21
Study: 8933241

Group type: EXPERIMENTAL
Intervention: Nitrate treatment
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Nontreatment (Control)
Number of subjects: 1002
Study: 1606457

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulant agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrinolytic agents
Number of subjects: 0
Study: 3918145

Group type: COMPARATOR
Intervention: Enteral formula containing 14% of its calories as protein
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enteral formula containing 22% protein calories
Number of subjects: 20
Study: 31590926

Group type: EXPERIMENTAL
Intervention: Pharmacist-led care coordination during transition from inpatient to community setting with follow-up medication therapy management (MTM) by community pharmacists.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Medication therapy management (MTM) provided by community pharmacists postdischarge.
Number of subjects: 96
Study: 29906916

Group type: EXPERIMENTAL
Intervention: Time-respecting null model randomization methodology
Number of subjects: 0